References
- Lowenstein DH, Alldredge BK. Status epilepticus at an urban public hospital in the 1980s. Neurology. 1993;43(3):483–488.
- Thundiyil JG, Rowley F, Papa L, et al. Risk factors for complications of drug-induced seizures. J Med Toxicol. 2011;7(1):16–23.
- Legriel S, Azoulay E, Resche-Rigon M, et al. Functional outcome after convulsive status epilepticus. Crit Care Med. 2010;38(12):2295–2303.
- Cheng JY. Latency to treatment of status epilepticus is associated with mortality and functional status. J Neurol Sci. 2016;370:290–295.
- Glauser T, Shinnar S, Gloss D, et al. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the Guideline Committee of the American Epilepsy Society. Epilepsy Curr. 2016;16(1):48–61.
- Kapur J, Elm J, Chamberlain JM, et al. Randomized trial of three anticonvulsant medications for status epilepticus. N Engl J Med. 2019;381(22):2103–2113.
- Ouzzani M, Hammady H, Fedorowicz Z, et al. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210.
- Messing RO, Closson RG, Simon RP. Drug-induced seizures: a 10-year experience. Neurology. 1984;34(12):1582–1586.
- Knudsen K, Heath A. Effects of self poisoning with maprotiline. Br Med J. 1984;288(6417):601–603.
- Li JM, Gan J, Zeng TF, et al. Tetramethylenedisulfotetramine intoxication presenting with de novo status epilepticus: a case series. Neurotoxicology. 2012;33(2):207–211.
- Cantrell FL, Wardi G, O’connell C. Propofol use for toxin-related seizures. Pharmacotherapy. 2016;36(6):702–704.
- Lee T, Warrick BJ, Sarangarm P, et al. Levetiracetam in toxic seizures. Clin Toxicol. 2018;56(3):175–181.
- Choosing Wisely [Internet]. Philadelphia (PA): ABIM Foundation; 2015 [cited 2020 Sep 5]. Available from: https://www.choosingwisely.org/clinician-lists/acmt-and-aact-phenytoin-or-fosphenytoin-to-treat-seizures/